Last reviewed · How we verify
LIS 18 U
At a glance
| Generic name | LIS 18 U |
|---|---|
| Also known as | subcutaneous insulin lispro |
| Sponsor | Dance Biopharm Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Dose-Response and Variability of Inhaled Insulin in Type 2 Diabetes (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LIS 18 U CI brief — competitive landscape report
- LIS 18 U updates RSS · CI watch RSS
- Dance Biopharm Inc. portfolio CI